Anixa Biosciences Inc (ANIX) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-03-11

Key Insights

Anixa Biosciences held its 2026 annual meeting of stockholders, with 20.8 million shares present or represented by proxy, representing 62% of the company's outstanding shares.
Shareholders re-elected the four incumbent directors, approved the company's executive compensation in a non-binding advisory vote, and ratified the appointment of Haskell & White LLP as the independent auditor for fiscal year 2026.
The presentation attached to the 8-K filing may be used by the company for future investor meetings, indicating the company's focus on communicating its business and strategies to the investment community.

Want the newest filings?

This analysis covers the filing from 2026-03-11. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-02-09

Anixa Biosciences reported encouraging patient survival data from its ovarian cancer CAR-T therapy Phase 1 clinical trial, indicating potential efficacy of the treatment.
The company received regulatory approval to escalate the dosage in the clinical trial beyond the original protocol, which could further improve the therapeutic potential of the CAR-T therapy.
The positive clinical trial results and dose escalation approval suggest the company is making progress in developing its novel cancer treatment, which could be a significant milestone for the business.

Other reports for Anixa Biosciences Inc

Quarterly Report Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.